ArticleInternational journal of cardiology. Congenital heart disease2022
Thromboembolic characteristics and role of anticoagulation in long-standing Fontan circulation.
Article in International journal of cardiology. Congenital heart disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Managing High Risk Pregnancy in Single Ventricle Physiology with Acquired von Willebrand Disease: A Case Report.Reports (MDPI) · 2025Article
- Thromboprophylaxis and adult congenital heart disease: The latest on indications, risk scoring and therapy.International journal of cardiology. Congenital heart disease · 2025Article
- Vitamin D deficiency and secondary hyperparathyroidism in adult Fontan patients.International journal of cardiology. Congenital heart disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The risk of thromboembolism increases with duration of Fontan circulation. Preventive drug strategies are still discussed controversially. We aimed to characterize clinical relevant thromboembolism in long-standing Fontan circulation and to analyse the protective effect of Acetylsalicylic acid (ASA) and Vitamin K Antagonists (VKA). Method: 78 patients (age ≥16 years) were included (mean age 20.7 ± 5.7 years; 51 male). Last medication and duration of therapy were documented. Perioperative events were excluded. Mean time of Fontan circulation was 21.1 ± 6.3 years, mean observation time 8.1 ± 5.6 years. Results: 44 patients were on VKA, 15 on ASA, 19 without treatment. Fifteen (19.2%) patients experienced thromboembolism. Nine patients had deep venous thromboses, among these five experienced pulmonary embolism. Four patients presented with supraventricular tachycardia (SVT), two with cerebral embolism and thrombus within the Fontan tunnel respectively. Two patients had an isolated thrombus in the Fontan tunnel. Time of Fontan circulation was significantly longer in thromboembolism (25.6 ± 8.3 years vs. 20.0 ± 5.2 years, p < 0.001). NYHA-class was worse (p = 0.03). Lacking treatment [OR 10.2 (95%CI 1.5-66.3)] and ASA [OR 1.25(95%CI)1.06-1.22] carried significantly higher risk of thromboembolism than VKA [OR 0.17 (95%CI 0.09-0.33)]. Kaplan-Meier analysis did n't differ in lacking treatment versus ASA (p = 0.2). VKA showed the best net-benefit regarding thromboembolism/bleeding complications (VKA: 11.4%, ASA 25%, VKA vs. lacking treatment 63.2%: p < 0.001). Conclusion: In long-standing Fontan circulation anticoagulation appears to be a safe treatment option to prevent late thromboembolism mainly caused by deep vein thrombosis and intracardiac thrombus formation associated with SVT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.